Novel Immunologic Approaches to Melanoma Treatment.
ACTAS DERMO-SIFILIOGRAFICAS 2017;
108:708-720. [PMID:
28527857 DOI:
10.1016/j.ad.2017.01.017]
[Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 01/15/2017] [Accepted: 01/31/2017] [Indexed: 01/06/2023] Open
Abstract
Approaches to treating melanoma have changed radically since the introduction of immunotherapy, and survival figures are now higher than possible with earlier therapies. The immunomodulators currently available mainly block CTLA-4 (cytotoxicT lymphocyte-associated molecule-4) and PD-1 (programed cell death protein 1) translocated to the cell surface, where they inhibit the antitumor immune response. Treatments blocking these molecules are being more widely used. Research now seeks new molecular targets, the best combinations of available drugs, and biomarkers that can identify ideal candidates for each one.
Collapse